Barbara Kosacz - 14 Feb 2024 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Reporting relationship: Director
Issuer ticker: CERO
Reported as of: 14 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Feb 2024, 19:40:38 UTC
Prior SEC filing: 05 Jan 2024
Next SEC filing: 17 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Chris Ehrlich, Attorney-in-Fact

Key filing fact

Barbara Kosacz filed Form 4 for PHOENIX BIOTECH ACQUISITION CORP. (CERO) on 16 Feb 2024.

Key facts

This page summarizes Barbara Kosacz's Form 4 filing for PHOENIX BIOTECH ACQUISITION CORP. (CERO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Feb 2024, 19:40.

Change

Previous filing in this sequence was filed on 05 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CERO transaction

Class A Common Stock

Other

Transaction value
Shares: +5,828
Change %
Price
Shares after: 5,828
Date: 14 Feb 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Barbara Kosacz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration.